Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Malaria: A Nested Cohort in a Trial of Radical Curative Regimens
In a cohort study within a clinical trial of radical cure regimens for malaria, Cindy S. Chu and colleagues assess the haemolytic risk associated with primaquine treatment among women heterozygous for glucose-6-phosphate dehydrogenase deficiency.
Published in the journal:
. PLoS Med 14(2): e32767. doi:10.1371/journal.pmed.1002224
Category: Research Article
In a cohort study within a clinical trial of radical cure regimens for malaria, Cindy S. Chu and colleagues assess the haemolytic risk associated with primaquine treatment among women heterozygous for glucose-6-phosphate dehydrogenase deficiency.
Primaquine is the only widely available drug that is effective against P. vivax hypnozoites, the latent forms that emerge from the liver to produce relapses of P. vivax malaria. The recommended regimen to prevent relapse of P. vivax malaria (called radical treatment) is primaquine given for 14 d at a daily dose of 0.25 to 0.5 mg base/kg. However, although widely recommended for radical treatment of P. vivax and P. ovale infections, primaquine is often not given. This is because primaquine causes haemolysis in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals . While G6PD deficiency is very common in malaria-endemic areas, G6PD testing is generally unavailable because the standard point-of-care test requires appropriate reagents, electricity, trained staff, and quality controls.
The point-of-care diagnosis of G6PD deficiency is usually made by a phenotypic screening test in which the G6PD-mediated reduction of NADP+ to NADPH is measured semiquantitatively. The standard test is the fluorescent spot test (FST), which assesses the fluorescence of NADPH in a blood spot under ultraviolet light . This identifies blood samples with ≳30%–40% activity as abnormal. It is considered safe to give primaquine (and other oxidant drugs) to persons who screen as having “normal” G6PD activity determined by the FST or other comparable rapid tests. The G6PD gene is on the X-chromosome. Hemizygous males and homozygous females have markedly reduced G6PD enzymatic activity and will therefore be identified reliably by these tests. However, in G6PD heterozygous females, random X-chromosome inactivation (Lyonisation)  results in red cell mosaicism. Individual red blood cells therefore express either a normal or deficient phenotype, so the overall blood G6PD activity level is an average determined by the relative proportions of the two red cell populations. The average proportion of deficient red cells in the population of heterozygotes is approximately half, but because random X-inactivation occurs early in embryogenesis, some women may have normal G6PD activity in the majority of their red cells, whereas others may have a majority of cells that are deficient. As a consequence, heterozygous females with a “normal” G6PD phenotype by the FST may have up to 60%–70% of their red blood cells that are G6PD deficient and susceptible to haemolysis by oxidant stresses.
Along the Myanmar border with northwestern Thailand, the prevalence of G6PD deficiency in males is 9%–18%. The Mahidol variant is most common (88% of all variants); other variants include Chinese-4, Viangchan, and Mediterranean type . As part of a dose optimisation trial to assess potentially simpler primaquine regimens for the radical treatment of P. vivax malaria in patients screened as “G6PD normal,” we report patterns of haemolysis in relation to the daily dose of primaquine and the G6PD genotype.
The trial was approved by the Faculty of Tropical Medicine, Mahidol University Ethics Committee (MUTM 2011–043, TMEC 11–008), and the Oxford Tropical Research Ethics Committee (OXTREC 17–11), and it was registered on the ClinicalTrials.gov website (NCT01640574).
Setting and Population
This nested cohort study was performed within a randomized nonblinded clinical trial in patients with acute P. vivax malaria. It was conducted by the Shoklo Malaria Research Unit (SMRU), which operates clinics extending over 120 km along the Thailand–Myanmar border. The clinics serve migrants and displaced persons of Burman and Karen ethnicities originating from as far as 30 km inside Myanmar.
Participants and Trial Procedures
Patients more than 6 mo old with symptomatic P. vivax mono-infection confirmed by microscopy were diagnosed in outpatient clinics and enrolled in the study if they or the carers of children < 18 y old gave fully informed written consent. Patients were excluded if they were G6PD deficient by FST or were pregnant or breastfeeding an infant ≤ 6 mo old, had severe malaria, an allergy to trial drugs, haematocrit ≤ 25%, or received a blood transfusion within 3 mo, or could not comply with the trial requirements. Enrolment investigations included malaria smear, haematocrit, G6PD FST, and full blood count.
Randomisation to each of four treatment arms was computer generated in blocks of 20. Assignment of the participant to a treatment arm was centralized; a phone call from the clinic-based study staff was made to an independent staff member not involved with the trial. Trial codes were given sequentially, and written confirmation was provided.
Participants were randomized to one of the following treatment regimens:
Chloroquine (Medopharm, India) 25 mg base/kg divided over 3 d (CQ) and primaquine (Utopian, Thailand) 1 mg base/kg/d for 7 d (PMQ-1)
CQ and primaquine 0.5 mg base/kg/d for 14 d (PMQ-0.5)
Dihydroartemisinin-piperaquine (Sigma-tau, Italy); dihydroartemisinin 7 mg/kg and piperaquine 55 mg/kg, divided over 3 d (DP) and PMQ-1
DP and PMQ-0.5
Treatment with all drugs began on the day of enrolment. Doses were calculated using charts with predefined weight bands (S1 Appendix). All primaquine doses were given after food and were supervised. Participants were seen weekly after treatment was completed.
Investigations included malaria smear, haematocrit, full blood count, G6PD phenotypic tests (described below), and G6PD genotyping for the prevalent Mahidol variant (487G>A). Capillary haematocrit was measured daily until day 7 and again on day 14. Haematocrit was measured on 30 μL of blood obtained via fingerstick using a heparinized capillary tube centrifuged at 10,000 rotations per minute (rpm) for 3 min and then read manually with a Hawksley Micro-Haematocrit reader. Anaemia requiring haematinic treatment was defined as an absolute haematocrit <30%. Haemoglobin variants were analysed using Capillary Electrophoresis (Capillarys2, SEBIA, France) in some patients with anaemia. The G6PD FST (R&D Diagnostic, Greece) was performed using 5 μL of blood mixed with 100 μL of reagents (containing haemolysing agents and NADP+ /G6P substrates). After 10 min of incubation at room temperature, a 15 μL aliquot was spotted on filter paper and allowed to dry in air. The spots were then examined under long-wavelength UV light (ca. 340 nm) to visualize the naturally fluorescent NAPDH; spots that fluoresced were classified as normal, and those that did not were classified as deficient. G6PD genotyping for Mahidol variant was performed on all female participants using an established PCR–RFLP protocol . In order to explain differences in haemoglobin reductions observed in heterozygous female participants with the same genotype, quantitative assessment of G6PD activity was performed at steady state 6 to 8 wk later and repeated twice per patient on two additional follow-up samples. Spectrophotometric quantitative assessment of G6PD enzymatic activity  was performed using the Trinity kit assay (Trinity Biotech, Ireland) in duplicate 10 μL whole blood samples. The absorbance at 340 nm at 30°C was measured over 10 min by a UV spectrophotometer (UV-1800, Shimadzu, Japan) with an electronically controlled temperature compartment. Estimated G6PD activity was calculated as the arithmetic mean of three repeated assessments and expressed per gram of haemoglobin (IU/gHb), as is commonly reported, and also per red blood cell (IU/RBC), which is considered more accurate in anaemic patients . Population median values and ranges for both assessments have been established previously in this population .
The primary outcome of this analysis was the fractional haematocrit reduction up to day 14 after enrolment. Secondary outcomes included a description of the temporal patterns of haemolysis and characterisation of the effects of the initial parasitaemia and G6PD activity on haematocrit reduction. A symptom sheet including common complaints was reviewed daily with each participant during study drug administration. Adverse events occurring after treatment completion were then collected passively and reported until day 42.
Laboratory data were processed by laboratory staff blinded to the clinical status of the participants. Subjective data (i.e., symptoms and adverse events) were collected by clinical study staff not involved with the study analysis. Because the main trial was not blinded, there may have been potential bias in extracting complaints of common adverse effects caused by primaquine; however, the G6PD genotype of all participants was unknown at the time of drug treatment.
In this population, the prevalence of G6PD deficiency in males has been determined previously to be around 14% (varying from 9% to 18% depending on the area and/or ethnic group) . Using this proportion as the allelic frequency and based on the Hardy-Weinberg principle, we expected 24% of females to be G6PD heterozygotes (varying from 15% to 30%) in the main trial. Because of the small sample size amongst heterozygote participants, we pooled the DP and CQ treatment regimens. Therefore, we analysed female participants in four groups:—by G6PD status—heterozygote and wild type, and—by primaquine dose—PMQ-0.5 and PMQ-1.
The hypothesis for this study was proposed before data collection, and the analysis was planned after data collection began. First, descriptive statistics were used to compare baseline participant characteristics between the four groups (as defined above). Then, a complete case analysis was performed; missing data were excluded. Haematocrit changes over time were normalized:
Unadjusted results were compared between groups and expressed as mean changes. A conservative estimate of a significant fractional haematocrit change was considered a priori to be +/− 15%—to take into account a technical variation of 10% and an actual 5% change . However, fractional haematocrit changes of +/− 25% have been more commonly considered as clinically significant , so both were assessed. Multivariable linear regression adjusted for initial parasitaemia was used to assess the following:
differences between groups in the mean of the maximum fractional haematocrit reduction (without and then with a test for interaction between G6PD genotype and primaquine dose; the interaction was added to the analysis in response to peer review);
the differences between groups in the estimated change in the mean of the maximum fractional haematocrit reduction per 10-fold increase in parasitaemia (including tests for interaction between initial parasitaemia and G6PD genotype and between initial parasitaemia and primaquine dose);
the association between the maximum fractional haematocrit reduction and quantitative G6PD activity determined by spectrophotometry (including tests for interaction between G6PD activity and G6PD genotype and between G6PD activity and primaquine dose).
Pearson’s correlation was used to determine the relationship between the mean of the maximum fractional haematocrit reduction and G6PD activity for the heterozygote groups. Multivariable logistic regression was used to assess differences between groups in the proportions of participants with fractional haematocrit reductions >15% and >25% unadjusted for initial parasitaemia (including a test for interaction between G6PD genotype and primaquine dose) and the presence of absolute haematocrit reductions below 30% (the threshold for anaemia treatment). The likelihood ratio test was used to determine whether the interactions were significant. Univariable logistic regression was used to assess symptoms during primaquine administration and adverse events between groups. Of the participants analysed, none were lost to follow up by day 14. Statistical analyses were performed using Stata version 13 (StataCorp, College Station, Texas, United States).
Between March 2012 and July 2014, 680 patients with acute P. vivax malaria and a normal G6PD FST were enrolled in the main trial. Details of all participants and the therapeutic outcomes will be reported elsewhere. Of the 241 female participants recruited, 34 (14%) were subsequently found to be G6PD Mahidol heterozygotes. One withdrew from the trial, leaving 33 with evaluable data (Fig 1). Symptoms, vital signs, and laboratory indices were similar in all treatment groups. G6PD heterozygous female participants taking PMQ-0.5 were younger (median 12 y [interquartile range (IQR) 7 to 27.5; range 1.5 to 45]) than heterozygous female participants taking PMQ-1 (19 y [IQR 14 to 27; range 6 to 38]) or wild-type female participants taking PMQ-1 (17 y [IQR 10.5 to 35; range 2 to 63]) or PMQ-0.5 (21 years [IQR 11 to 38; range 3 to 60]) (Table 1). Children less than 5 y old were under-represented in the heterozygous female PMQ-1 group.
The effect of primaquine dose on haemolysis was different in G6PD wild-type and G6PD heterozygous female participants (p = 0.0104 for interaction). There was no evidence of primaquine dose-dependent haemolysis in G6PD wild-type female participants when comparing PMQ-1 and PMQ-0.5, and there were no differences when comparing the CQ and DP groups (S1 Table). In contrast, primaquine was associated with clear dose-dependent haemolysis in G6PD heterozygous female participants. In the pooled analysis (CQ+DP) of G6PD heterozygous female participants, unadjusted for parasitaemia, 14/17 (82%) in the PMQ-1 group had fractional haematocrit reductions >15% compared with 6/16 (38%) G6PD heterozygous female participants in the PMQ-0.5 group (odds ratio [OR] 7.8 [95% CI 1.6 to 38.8]; p = 0.012). When comparing the proportions of G6PD heterozygous female participants with a fractional haematocrit reduction of >25%, the results were similar: 9/17 (53%) in the PMQ-1 group had fractional haematocrit reductions >25% compared with 2/16 (13%) G6PD heterozygous female participants in the PMQ-0.5 group (OR 7.9 [95% CI 1.4 to 45.8]; p = 0.022).
Among G6PD heterozygous female participants who took PMQ-1 with DP, the haematocrit reached its nadir on day 5 with a mean fractional reduction of −23.2% (SD 11.0) compared to −16.5% (SD 7.4) on day 6 in those taking PMQ-0.5. In the CQ group, the haematocrit reached its nadir on day 4 with a mean fractional reduction of −16.4% (SD 7.9) with PMQ-1 compared to −11.9% on day 5 (SD 11.1) with PMQ-0.5 (S1 Table). Irrespective of primaquine dose, by day 7 the mean fractional haematocrit rose again in all groups (except for three G6PD wild-type participants) despite continued primaquine administration (Fig 2 and S2 Table). In the pooled analysis, unadjusted for parasitaemia and including a test for interaction between G6PD genotype and primaquine dose, the effect of primaquine dose on haemolysis remained different in G6PD wild-type and G6PD heterozygous female participants (p = 0.0018 for interaction). The mean maximum individual fractional haematocrit reduction (mean of the individual nadirs) was similar between G6PD wild-type female participants taking PMQ-1 and PMQ-0.5, but in G6PD heterozygous female participants, it was significantly greater in the PMQ-1 group (−23.6% [95% CI −27.0% to −20.2%]) compared with the PMQ-0.5 group (−15.5% [95% CI −19.0% to −12.0%]), with a mean difference of −8.1% (95% CI −13.0% to −3.2%; p = 0.001) (Fig 3 and Table 2). When the same analysis was performed adjusting for parasitaemia, the effect of genotype and dose was reduced significantly, and the interaction of primaquine dose on haemolysis remained different in G6PD wild-type and G6PD heterozygous female participants (p = 0.0014 for interaction) (Tables 2 and 3). The estimated change in the mean maximum fractional haematocrit per 10-fold increase in initial parasitaemia in G6PD wild-type female participants (without testing for interaction between G6PD genotype and primaquine dose) was −2.9% (95% CI −5.1% to −0.60%; p = 0.012) in the PMQ-1 group and −2.0% (95% CI −4.1% to 0.06%; p = 0.056) in the PMQ-0.5 group. Corresponding values for heterozygous female participants were 1.5% (95% CI −3.0% to 6.0%; p = 0.503) in the PMQ-1 group and 2.4% (95% CI −2.3% to 7.0%; p = 0.315) in the PMQ-0.5 group.
The median interval to the nadir of haematocrit reduction was 3 d (IQR 2 to 5) in wild-type female participants in the PMQ-1 group and 3.5 d (IQR 2 to 6) in the PMQ-0.5 group. In heterozygous female participants, the corresponding values were 5 d (IQR 4 to 6) in both groups.
Haemolysis and Quantitative G6PD Activity
G6PD activity was measured in 21 heterozygous females and 21 control wild-type females at steady state, i.e., at least 6 wk after recruitment when the participants had recovered fully. After controlling for initial parasitaemia and including tests for interaction between G6PD activity and genotype (the interaction term between G6PD genotype and primaquine dose was not significant, so it was not included in the model), there was no correlation between the mean individual fractional haematocrit reduction and G6PD activity expressed as IU/gHb within any group. However, when expressed in IU/RBC, there was stronger evidence of a relationship. In the PMQ-1 group, the reduction in haematocrit for heterozygous females was 3.1% less (95% CI 0.66% to 5.44%; p = 0.014) for a 10% higher level of G6PD activity and 3.2% less (95% CI 0.83% to 5.54%; p = 0.009) in the PMQ-0.5 group (Fig 4).
Symptom Reporting and Adverse Events
The incidence of anaemia requiring haematinic treatment within the first 42 d from enrolment, defined as an absolute haematocrit <30%, was not different between heterozygote females who received PMQ-1 (11/17 [65%]) or PMQ-0.5 (6/16 [38%]) (OR 2.1 [95% CI 0.47 to 9.3]; p = 0.328). When comparing G6PD heterozygous and wild-type females in the PMQ-1 group, the heterozygotes were significantly more likely to require haematinic treatment (OR 8.9 [95% CI 2.6 to 30.6]; p = 0.001). A similar result was found when comparing G6PD heterozygous females in the PMQ-1 group with the wild-type females in the PMQ-0.5 group (OR 5.3 [95% CI 1.68 to 16.4]; p = 0.004). The only participants requiring blood transfusion were two heterozygous females who received PMQ-1; recovery occurred without further complications (Table 4). Active and passive reporting of symptoms potentially associated with haemolysis (headache, backache, abdominal pain, muscle pain, dizziness, palpitations, and fatigue) during study drug administration was similar in the different groups. Abdominal pain was not different between participants in the PMQ-1 compared to the PMQ-0.5 groups (OR 1.9 [95% CI 0.71 to 5.0], p = 0.201).
These results show that the standard high dose primaquine regimen given over 14 d (0.5 mg base/kg/d) is reasonably well tolerated by G6PD Mahidol heterozygous female participants, whereas significant haematocrit reductions (fractional haematocrit reduction >25%) were observed in those taking the higher daily dose (same total dose) given over 7 d (1 mg base/kg/d). Two heterozygous participants receiving the higher primaquine dose given over 7 d (1 mg base/kg/d) required transfusion. G6PD Mahidol wild-type female participants did not have an increased risk of primaquine-induced haemolysis when taking the same dose. Irrespective of primaquine regimen and despite continued dosing, haematocrits increased by day 7. The lack of subjective complaints and change in vital signs suggests that haematocrit declines were tolerated and these symptoms and signs did not identify moderate or even severe degrees of haemolysis .
Relapse in vivax malaria is a major cause of morbidity in tropical countries and in areas of high transmission contributes to mortality in young children from severe anaemia [12,13]. Prevention of relapse (radical cure) requires use of 8-aminoquinoline drugs, with the attendant risk of haemolysis in patients who are G6PD deficient. Since primaquine was introduced 65 y ago, it has been widely recommended and widely not given. This is because screening tests for G6PD deficiency have not been available generally, and the potential risks of giving primaquine unwittingly to a deficient patient were considered to outweigh the overall benefits . Those risks depend on the degree of deficiency, determined by the G6PD genotype, and the exposure to the oxidant metabolites of primaquine, determined largely by the dose and the ability to metabolise the parent compound (reflecting in part cytochrome 2D6 activity and thus the 2D6 genotype) [15,16]. However, increased deployment of radical treatment is necessary if the enormous burden of vivax malaria is to be reduced, and this is being encouraged strongly . To this end, simple point-of-care tests for G6PD deficiency have been developed to guide treatment. These tests have similar performance characteristics to the conventional NADPH FST and so will reliably identify G6PD homozygous females and hemizygous males, but, as this study illustrates clearly, tests with a detection threshold of ≳30%–40% of normal activity do not identify a large proportion of female heterozygotes. There is a significant dose-dependent haemolytic risk in some of these patients [18,19].
Although there are now more than 200 different G6PD deficiency genotypes described, usually resulting in an unstable enzyme, there is substantial phenotypic variability within genotypes, so severe haemolysis can still occur with so called “mild variants.” Amongst the more common G6PD variants globally, the African A-genotype is at the mild end of the spectrum, and the Mediterranean variant is at the severe end. The Mahidol variant studied in this trial is associated with low G6PD activities in hemizygous males, suggesting it is towards the severe end of the spectrum. Oxidant haemolysis in G6PD deficiency results in loss of the most deficient cells. In most deficiencies, these are the older and mature erythrocytes in which the unstable enzyme activity has declined such that oxidant defences can no longer be maintained. As these cells are haemolysed, they are replaced by young red cells from the bone marrow with much higher levels of enzyme activity. These young erythrocytes are therefore relatively resistant to oxidant stresses and are less likely to haemolyse . As a result, in all but the most severe deficiencies, there is an initial fall in haemoglobin followed by a rise despite continued drug administration [21,22]. P. vivax malaria is also associated with haemolytic anaemia. In this study, primaquine had a negligible additional haemolytic effect over that caused by P. vivax malaria in women who were wild type for the G6PD Mahidol variant. However, heterozygous females with P. vivax malaria who had screened as “normal” (which suggests at least ≳30%–40% of their red blood cell population had normal levels of G6PD activity) experienced significant additional haemolysis as a result of taking a higher dose of primaquine over 7 d (1 mg base/kg/d). Although the potential for severe haemolysis in female G6PD heterozygotes has been well recognised , this has been little studied. In this study, haemolysis was dose dependent, as reported previously in hemizygous males . Heterozygous females who received a higher primaquine dose of 1 mg base/kg/d haemolysed significantly more and required more treatment of their anaemia than those receiving the standard high 0.5 mg base/kg/d dose. Despite this, the haematocrit started to rise again, usually after the fifth day, as the new young red cells with higher levels of G6PD enzyme activity entered the circulation. This suggests that strategies to attenuate primaquine haemolytic toxicity by dose spacing should reduce risks in G6PD heterozygotes with the Mahidol variant but that starting radical treatment with higher daily individual doses of 8-aminoquinolines is potentially dangerous if blood transfusion is not immediately available.
Unfortunately, this relatively common, potentially high-risk group is not identified by current screening tests. Even the “gold standard” spectrophotometric assay of average erythrocyte G6PD activity (expressed as IU/gHb), which certainly cannot be performed widely in the rural tropics, showed a poor correlation with haemolytic toxicity. When spectrophotometric results were expressed as IU/RBC, a correlation was evident, which suggests that quantitative methods used to measure G6PD activity should be adjusted in anaemic populations. Handheld point-of-care quantitative testing methods and other qualitative tests of G6PD deficiency are being developed with detection thresholds of ~70% activity. The performance of these new methods and the number of truly normal (i.e., wild-type genotypes) individuals these tests may misidentify as G6PD deficient remain to be assessed.
There are a number of limitations in this analysis. Firstly, the primary trial was not designed specifically to address primaquine-induced haemolysis in G6PD heterozygous females. The number of heterozygous female participants was small, and pooling the CQ and DP groups by primaquine regimens was necessary. As with chloroquine, dihydroartemisinin-piperaquine has been shown to increase primaquine plasma concentrations , but it is not known whether bioactive metabolites are higher or lower than chloroquine. Because of the small number of participants analysed, conclusions could not be made on the relationship of haemoglobin type with G6PD deficiency, haemolysis, and anaemia after treatment with primaquine. There was a paucity of data in heterozygous females with enzymatic activity in the range of 40% to 60% of normal who took PMQ-0.5, and the fractional haematocrit reductions during primaquine administration in this group require further confirmation.
For the present, the practical therapeutic implications of these findings are that, for areas where G6PD deficiency genotypes of similar or greater severity to G6PD Mahidol are prevalent, daily primaquine doses greater than 0.5 mg base/kg/d should not be given to female patients irrespective of the G6PD screening result unless they can be closely monitored. More information is needed on haemolytic patterns and haemolytic risk in patients with G6PD Mahidol and other G6PD deficiency genotypes and with point-of-care quantitative testing when it becomes more widely available. Safer methods of giving primaquine are needed.
1. Beutler E. The hemolytic effect of primaquine and related compounds: a review. Blood. 1959;14: 103–139. 13618370
2. Beutler E, Mitchell M. Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. Blood, J Hematol. 1968;32: 816–818.
3. Luzzatto L. Glucose 6-phosphate dehydrogenase deficiency: from genotype to phenotype. Hematol J. 2006;91: 1303–1306.
4. Bancone G, Chu CS, Somsakchaicharoen R, Chowwiwat N, Parker DM, Charunwatthana P, et al. Characterization of G6PD Genotypes and Phenotypes on the Northwestern Thailand–Myanmar Border. PLoS ONE. 2014;9: e116063. doi: 10.1371/journal.pone.0116063 25536053
5. Nuchprayoon I, Louicharoen C, Charoenvej W. Glucose-6-phosphate dehydrogenase mutations in Mon and Burmese of southern Myanmar. J Hum Genet. 2008;53: 48–54. doi: 10.1007/s10038-007-0217-3 18046504
6. Beutler E, Blume KG, Kaplan JC, Löhr GW, Ramot B, Valentine WN. International Committee for Standardization in Haematology: Recommended Methods for Red-Cell Enzyme Analysis*. Br J Haematol. 1977;35: 331–340. 857853
7. WHO Scientific group. World Health Organization Standardization of procedures for the study of glucose-6-phosphate dehydrogenase. World Health Organ Tech Rep Ser. 1967. pp. 1–53.
8. Bancone G, Chu CS, Chowwiwat N, Somsakchaicharoen R, Wilaisrisak P, Charunwatthana P, et al. Suitability of Capillary Blood for Quantitative Assessment of G6PD Activity and Performances of G6PD Point-of-Care Tests. Am J Trop Med Hyg. 2015;92: 818–824. doi: 10.4269/ajtmh.14-0696 25646252
9. Morris SS, Ruel MT, Cohen RJ, Dewey KG, de la Brière B, Hassan MN. Precision, accuracy, and reliability of hemoglobin assessment with use of capillary blood. Am J Clin Nutr. 1999;69: 1243–1248. 10357746
10. Kheng S, Muth S, Taylor WRJ, Tops N, Kosal K, Sothea K, et al. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency. BMC Med. 2015;13: 203. doi: 10.1186/s12916-015-0441-1 26303162
11. Hockwald RS, Arnold J, Clayman CB, Alving AS. Toxicitiy of Primaquine in Negroes. J Am Med Assoc. 1952;149: 1568–1570. 14945981
12. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008;5: e128. doi: 10.1371/journal.pmed.0050128 18563962
13. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, et al. Vivax Malaria: A Major Cause of Morbidity in Early Infancy. Clin Infect Dis. 2009;48: 1704–1712. doi: 10.1086/599041 19438395
14. World Health Organization. Guidelines for the treatment of malaria, 2nd Edition. Geneva: WHO Press; 2010.
15. Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Toxicol Appl Pharmacol. 2009;241: 14–22. doi: 10.1016/j.taap.2009.07.012 19616568
16. Fasinu PS, Tekwani BL, Nanayakkara NDPD, Avula B, Herath HBMTB, Wang Y-H, et al. Enantioselective metabolism of primaquine by human CYP2D6. Malar J. 2014;13: 507. doi: 10.1186/1475-2875-13-507 25518709
17. World Health Organization. Guidelines for the treatment of malaria, 3rd Edition. Geneva: World Health Organization; 2015.
18. Alving AS, Kellermeyer RW, Tarlov AR, Schrier SL, Carson PE. Biochemical and Genetic Aspects of Primaquine-sensitive Hemolytic Anemia. Ann Intern Med. 1958;49: 240. 13571815
19. Tarlov AR, Brewer GJ, Carson PE, Alving AS. Primaquine sensitivity. Glucose-6-phosphate dehydrogenase deficiency: an inborn error of metabolism of medical and biological significance. Arch Intern Med. 1962;109: 209–234. 13919680
20. Beutler E, Dern RJ, Alving AS. The hemolytic effect of primaquine IV. The relationship of cell age to hemolysis. J Lab Clin Med. 1954;44: 439–442. 13201853
21. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13: 418. doi: 10.1186/1475-2875-13-418 25363455
22. Recht J, Ashley EA, White NJ. Safety of 8-Aminoquinoline Antimalarial Medicines. Geneva: World Health Organization; 2014.
23. Luzzatto L, Seneca E. G6PD deficiency: A classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014;164: 469–480. doi: 10.1111/bjh.12665 24372186
24. Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W, et al. Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects. Antimicrob Agents Chemother. 2014;58: 7340–7346. doi: 10.1128/AAC.03704-14 25267661
Článek vyšel v časopise
2017 Číslo 2
- Příznivý vliv Armolipidu Plus na hladinu cholesterolu a zánětlivé parametry u pacientů s chronickým subklinickým zánětem
- Berberin: přírodní hypolipidemikum se slibnými výsledky
- Armolipid Plus – doplněk stravy s potvrzeným účinkem na dyslipidemii
- Nutraceutikum Armolipid Plus podle klinických důkazů zlepšuje lipidový profil − metaanalýza
- Červená fermentovaná rýže účinně snižuje hladinu LDL cholesterolu jako vhodná alternativa ke statinové terapii
Nejčtenější v tomto čísle
- Refining Lung Cancer Screening Criteria in the Era of Value-Based Medicine
- Renewing ’s editorial board in times of global distraction
- Hope for HIV control in southern Africa: The continued quest for a vaccine
- Precision oncology: Charting a path forward to broader deployment of genomic profiling
Zvyšte si kvalifikaci online z pohodlí domova